Aura Biosciences (AURA) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

-$0.37

Surprise

—

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement Wit — benzinga, 2026-08-11
• HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18 — benzinga, 2026-08-11
• Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate — benzinga, 2026-08-11

TrendMatrix currently rates AURA Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$7.80

Price target

$14.44

Stop

$7.25

Upside to target

+85.1%

Reward-to-risk

6.6:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$808.9M

P/E (fwd)

-3.8

52-week range

$4.73–$9.54

Off 52-week high

18.2%

RSI (14)

63

Volume vs avg

0.68×

Score today

5.3/10